Literature DB >> 7836025

Pharmacokinetic study of rifaximin after oral administration in healthy volunteers.

J J Descombe1, D Dubourg, M Picard, E Palazzini.   

Abstract

Eighteen healthy male volunteers, with a mean age of 24 yrs (range 18-40), underwent an open pharmacokinetics study, aimed at detecting rifaximin concentration in blood and urine after a single oral administration of 400 mg of the antibiotic. Administration took place after a 9 hours' fast and was followed by a breakfast after 2 hours and a lunch after 5 hours. Blood samples were collected before rifaximin administration and 1, 2, 4, 8, 12, 24 and 48 hours after dosing. Urine samples were collected immediately before dosing (reference sample) and then at the end of the following intervals of time: 0-6 h, 6-12 h, 12-24 h, 24-48 h. During the whole study period, the local and general tolerance to rifaximin administration was checked. Rifaximin concentration was assessed by reversed phase high performance liquid chromatography with electrochemical detection. In almost every plasma sample, rifaximin concentration was undetectable (lower than the detection limit of the analytical method, i.e. 2 ng/ml). In urine, very small amounts of the unchanged molecule (< 0.01% of the administered dose) were found in the period 0-48 hours. These results confirm the negligible absorption by the intestinal tract of a single oral dose of rifaximin (400 mg). Local and general tolerance of the administered drug was very good.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7836025

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Res        ISSN: 0251-1649


  35 in total

1.  Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial.

Authors:  P Gionchetti; F Rizzello; A Ferrieri; A Venturi; C Brignola; M Ferretti; S Peruzzo; M Miglioli; M Campieri
Journal:  Dig Dis Sci       Date:  1999-06       Impact factor: 3.199

Review 2.  Future novel therapeutic agents for Clostridium difficile infection.

Authors:  Hoonmo L Koo; Kevin W Garey; Herbert L Dupont
Journal:  Expert Opin Investig Drugs       Date:  2010-07       Impact factor: 6.206

Review 3.  Prevention and self-treatment of traveler's diarrhea.

Authors:  David J Diemert
Journal:  Clin Microbiol Rev       Date:  2006-07       Impact factor: 26.132

4.  Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.

Authors:  S M Finegold; D Molitoris; M-L Väisänen
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

Review 5.  Rifaximin: a review of its use in the management of traveller's diarrhoea.

Authors:  Gayle W Robins; Keri Wellington
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 6.  Understanding and controlling chronic immune activation in the HIV-infected patients suppressed on combination antiretroviral therapy.

Authors:  Babafemi Taiwo; Luis Barcena; Randall Tressler
Journal:  Curr HIV/AIDS Rep       Date:  2013-03       Impact factor: 5.071

7.  The effect of rifaximin on gut flora and Staphylococcus resistance.

Authors:  Mi-Sung Kim; Walter Morales; Andres Ardila Hani; Sharon Kim; Gene Kim; Stacy Weitsman; Christopher Chang; Mark Pimentel
Journal:  Dig Dis Sci       Date:  2013-04-16       Impact factor: 3.199

8.  Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study.

Authors:  Yong Han Paik; Kwan Sik Lee; Kwang Hyub Han; Kun Hoon Song; Myoung Hwan Kim; Byung Soo Moon; Sang Hoon Ahn; Se Joon Lee; Hyo Jin Park; Dong Ki Lee; Chae Yoon Chon; Sang In Lee; Young Myoung Moon
Journal:  Yonsei Med J       Date:  2005-06-30       Impact factor: 2.759

Review 9.  Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases.

Authors:  Hoonmo L Koo; Herbert L DuPont
Journal:  Curr Opin Gastroenterol       Date:  2010-01       Impact factor: 3.287

10.  The role of rifaximin in the treatment and chemoprophylaxis of travelers' diarrhea.

Authors:  Hoonmo L Koo; Herbert L Dupont; David B Huang
Journal:  Ther Clin Risk Manag       Date:  2009-11-02       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.